
Is there any such thing as a safe investment?
In 1997, just before I left for college, I took nearly two decades' worth of these savings bond gifts to my bank. The face values added up to no more than $1,000 total. I redeemed my savings bonds for an amount closer to $2,000. I walked out of the bank feeling like I had the Power of Grayskull.
The little old ladies in my family were onto something with those second-rate birthday gifts (that came with principal protection and a decent return). I wondered if I should listen when these wise elders also advised me to put my money in other 'safe' investments, like real estate, gold, and annuities.
But as smart as my aunts and grandmothers were, the past 30 years has me wondering if there is such a thing as a safe investment. Here's what I've come to understand about the low-risk investments that are traditionally considered safe.
In the mid-2000s, the accepted wisdom about real estate was that home values could only go up and an upside-down mortgage was an economic impossibility. Which explains why banks were throwing bags of money at anyone with real estate dreams and a verifiable pulse.
Back then, I was still teaching high school English and not paying close attention to financial or housing news—but the explosion of house-flipping reality TV weirded me out.
Many of these shows documented photogenic amateurs overleveraging their finances and DIY skills to remodel cheap homes for a quick profit. Considering how common these shows were, and how incompetent many of the flippers were, it struck me that the demand for housing couldn't possibly remain high enough to keep up with this kind of supply.
Unfortunately, by 2008 the housing bubble had burst. Apparently, real estate values can go down and a borrower can be upside down in a mortgage.
The subsequent great recession was a painful reminder that real estate isn't a straightforward path to generational wealth, no matter what the 'Welcome to the American Dream' brochure may say.
The risky fine print
When your grandmother suggested that buying a house was a smart and safe investment, she wasn't thinking about you taking out an adjustable rate mortgage to purchase a foreclosed fixer-upper to renovate and sell in less than six months.
For the majority of real estate investors (i.e., homeowners) buying a house is more about securing shelter than investing money for a future financial payout. That's what Nana meant when she called buying a house a smart investment. Becoming a homeowner will not only provide you and your family with something you need, but your home will also appreciate in value over time—as measured, traditionally, in years or decades rather than months or quarters.
But if you're counting on turning a quick profit, you may be in for a rude awakening—just ask any real estate developer. The safety of such a real estate investment is the fact that you build equity and value as the years pass in your home.
Gold
Humans have prized gold for its beauty and malleability for millennia. We have adorned ourselves and our homes with golden decorations for at least the past 6,000 years, and we began using gold as currency about 1,500 years ago. Since gold resists corrosion and oxidation, it's an ideal medium for currency, since it holds its value better than a metal that rusts, corrodes, or becomes hollowed out in a can of Coke (allegedly).
But gold doesn't just hold its value over time. Between our collective fascination with its glitter and the durability of this malleable metal, the value of gold has generally risen over time. Typically, the price of gold spikes during periods of economic or political uncertainty. Investors appreciate the tangible confidence of an investment in gold, especially if they have just experienced major losses in the market.
The risky fine print
It's unlikely that the relationship between humanity and gold will go away anytime soon. So buying gold probably isn't a bad idea. But that doesn't mean it should be the cornerstone of anyone's investment strategy.
For example, in the past 30 years, the S&P 500 has averaged a 10.29% compound annual growth rate, while gold's spot price has a 6.97% compound annual growth rate. Just under 7% compound annual growth is certainly not nothing, but gold experienced negative growth for 11 of the 30 years, compared to only six for the S&P 500. Ultimately, gold was more volatile.
In addition, scammers often prey on investors hoping to put their money into safe investments like gold. While a legitimate investment in gold may be a prudent investing decision, treating all gold investments as 'safe' could leave you vulnerable to fraud.
It may be easier to think of gold as 'safe' in the same way that cash can be safe. In some situations, it's helpful and prudent to have, but in others, it can cost you.
Annuities
Before I started writing about money, I associated annuities with people who knit. That's because the only people who ever seemed to discuss them were friends of Miss Marple in Agatha Christie mysteries and my elderly relatives.
Of course, once I became a financial journalist, I learned that an annuity is an insurance contract and that knitting is rarely required. Typically, you'll pay the insurance company either through a series of payments or via a lump sum, and they'll give you monthly payments for a specific period of time, death benefits, and tax-free growth on your investment. Annuities may offer fixed interest rates, variable interest rates, or rates tied to a specific stock market index.
Since you purchase an annuity through an insurance company, the safety of your money is ensured by the company's financial rating. The annuity will also do the hard work of budgeting your money for you, sending you monthly payments that re-create the experience of having a salary postretirement. That makes it a safe and smart way to offload your financial chores to the insurance company.
The risky fine print
Of course, annuities aren't all yarn balls and tea cozies. To start, since annuities are an insurance product, they may be sold by high-pressure insurance agents who want a commission and don't care if the annuity fits your needs.
Additionally, while some annuities are straightforward and easy-to-understand products, there are a number of much more complex annuities that may not be clear at first glance. It's important to make sure you understand exactly what product you're getting, what it is supposed to do to help you reach your goals, why the insurer thinks it fits your needs, how it works, when it will begin to pay out, what fees it may have, etc.
Finally, the biggest risk to annuities is the fact that your money is tied up in the annuity. If you want to withdraw funds early, you will have to pay a surrender charge, which can be as high as 7% of the amount you withdraw.
Understanding the meaning of 'safe'
Sometimes, the wisdom of our elders gets lost in translation.
When Nana sent savings bonds instead of Battle Armor He-Man, she was giving a gift for your future self to appreciate.
When she told you real estate was a good investment, she was encouraging you to settle down—and enjoy the side benefit of your money growing.
When she shared how her own grandmother sewed family gold into her petticoat and used it to barter her way to America, she was teaching you how to protect yourself in a chaotic world.
When she crowed about her annuity, she wanted you to know there are ways to relieve yourself of the work you hate doing without giving up anything you need.
When you understand what someone means when they call an investment safe—especially when it's someone as wise as one of your family elders—then you can recognize how to take their advice and avoid the unnecessary risk.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
XAI Madison Equity Premium Income Fund Declares its Monthly Distribution of $0.060 per Share
CHICAGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (the 'Fund'), has declared its regular monthly distribution of $0.060 per share on the Fund's common shares (NYSE: MCN) payable on September 2, 2025. The amount represents no change from the previous month's distribution amount. As mentioned in previous distribution declarations, the Fund has changed its distribution frequency from quarterly to monthly, which went into effect with the April 1, 2025 declaration. XA Investments believes this change enables investors to better manage their cash flow needs. Ex-Dividend Date August 15, 2025 Record Date August 15, 2025 Payable Date September 2, 2025 Amount $0.060 per share Change from Previous Month No Change The following dates apply to the declaration: Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund's common shareholders on Form 1099 after the end of the 2025 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund's distributions, please visit . The Fund's net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund's final taxable income for the current fiscal year will not be known until the Fund's tax returns are filed. As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund's fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so. The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder's tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder's potential gain, or reduce the common shareholder's potential loss, on any subsequent sale or other disposition of common shares. Future common share distributions will be made if and when declared by the Fund's Board of Trustees, after the evaluation of several factors, including the Fund's net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future. The Fund's objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund's total assets affect the Fund's future dividend prospects. The Fund provides additional information on its website at . About XA Investments XA Investments LLC ('XAI') serves as the Fund's investment adviser. XAI is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. The listed closed-end funds, the XAI Octagon Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund, Octagon XAI CLO Income Fund is available via direct subscription and through select broker/dealers and wealth management platforms. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including development and market research, sales, marketing, and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XAI provides individual investors with access to institutional-caliber alternative managers. For more information, please visit . About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit . About Madison Investments Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.3 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit .Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority . XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund's webpage at . This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Media Contact:Kimberly Flynn, PresidentXA Investments LLCPhone: 888-903-3358Email: KFlynn@ in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
US securities regulator announces AI task force
(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision